BRCA1 and anemia (phenotype): Among men with grade 3-4 anemia, 56.4% (22/39) had BRCA1/2 alterations and 72.7% (16/22) of these men had a duration of treatment 6 months or longer versus 56.4% (22/39) of men in the overall population with grade 3-4 anemia.